If validated in larger, confirmatory studies, this may in fact represent new possibilities for targeted therapy for NSCLC patients, using gender, miRNA and hormone receptor expression as therapy selection criteria. The gene discussed is NR4A1; the disease is non-small cell lung carcinoma.